Top biologic drugs by share of total drug costs in Canadian public plans 2021/2022
This statistic depicts the top biologic drugs by share of total drug costs within select Canadian public drug plans in 2021/2022. Top listed biologic drug was Eylea (aflibercept) with a 3.8 percent share of total drug costs that year.